The estimated Net Worth of Daniel E Handley is at least $113 Thousand dollars as of 15 December 2022. Daniel Handley owns over 6,000 units of Predictive Oncology stock worth over $113,282 and over the last 4 years he sold POAI stock worth over $0. In addition, he makes $0 as Director at Predictive Oncology.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Daniel Handley POAI stock SEC Form 4 insiders trading
Daniel has made over 4 trades of the Predictive Oncology stock since 2022, according to the Form 4 filled with the SEC. Most recently he bought 6,000 units of POAI stock worth $2,460 on 15 December 2022.
The largest trade he's ever made was buying 10,000 units of Predictive Oncology stock on 29 November 2022 worth over $3,600. On average, Daniel trades about 1,017 units every 10 days since 2020. As of 15 December 2022 he still owns at least 120,513 units of Predictive Oncology stock.
You can see the complete history of Daniel Handley stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Daniel Handley biography
Dr. Daniel Handley Ph.D. serves as Director of the Company. He serves as a Professor and the Director of the Clinical and Translational Genome Research Institute of Southern California University of Health Sciences. Previously, he was the Chief Scientific Officer of the Clinical and Translational Genome Research Institute, a Florida 501(c)(3) non-profit corporation. During that time, he also held a courtesy faculty appointment in the Department of Biological Sciences at Florida Gulf Coast University. He previously served as the Chief Scientific Officer for Advanced Healthcare Technology Solutions, Inc., Life-Seq, LLC, as a senior researcher at the Procter & Gamble Co., a senior administrator, researcher, and laboratory manager at the David Geffen UCLA School of Medicine, and as a founding biotechnology inventor for the National Genetics Institute. He holds a B.A. in Biophysics from Johns Hopkins University, an M.S. in Logic and Computation from Carnegie Mellon University, and a Ph.D. in Human Genetics from the University of Pittsburgh. He completed his post-doctoral training at Magee-Women’s Research Institute researching advanced genomic technologies applied to fetal and maternal health. He is a decorated veteran of the U.S. Navy, having served as a nuclear propulsion instructor and a submarine nuclear reactor operator.
How old is Daniel Handley?
Daniel Handley is 59, he's been the Director of Predictive Oncology since 2020. There are 7 older and 2 younger executives at Predictive Oncology. The oldest executive at Predictive Oncology Inc. is Dr. Carl I. Schwartz, 79, who is the CEO & Director.
What's Daniel Handley's mailing address?
Daniel's mailing address filed with the SEC is 2867 STRATHALLAN AVENUE, , HENDERSON, NV, 89044.
Insiders trading at Predictive Oncology
Over the last 5 years, insiders at Predictive Oncology have traded over $30,944 worth of Predictive Oncology stock and bought 417,770 units worth $148,589 . The most active insiders traders include Carl I. Schwartz, J Melville Engle, and Charles Lee Sr Nuzum. On average, Predictive Oncology executives and independent directors trade stock every 71 days with the average trade being worth of $29,495. The most recent stock trade was executed by Robert L Myers on 25 September 2023, trading 1,667 units of POAI stock currently worth $1,584.
What does Predictive Oncology do?
Predictive Oncology Inc., a knowledge-driven company, focuses on developing personalized cancer therapies using artificial intelligence (AI) primarily in the United States. The company operates in four segments: Helomics, zPREDICTA, Soluble, and Skyline. The Helomics segment offers clinical testing services comprising tumor drug response testing and genomic profiling tests; and contract research services through patient-centric drug discovery using active learning technology for discovery, clinical and translational research, clinical trials, and diagnostic development and validation. The zPREDICTA segment develops organ-specific disease models that provide 3D reconstruction of human tissues representing each disease state and mimicking drug response for testing of anticancer agents. The Soluble segment provides services using High-Throughput Self-Interaction Chromatography, a self-contained, automated system that conducts high-throughput, self-interaction chromatography screens using additives and excipients that are included in protein formulations for soluble and physically stable formulations for biologics. This segment also offers protein stability analysis services; protein solubility kits that allow rapid identification of soluble formulations; and proprietary technologies for bacterial endotoxin detection and removal. The Skyline segment provides STREAMWAY System, a wall-mounted fully automated system, which virtually eliminates staff exposure to blood, irrigation fluid, and other infectious fluids found in the healthcare environment. It also offers research and development services; and media that help cancer cells grow outside the patient's body and retain their DNA/RNA and proteomic signatures. The company was formerly known as Precision Therapeutics Inc. and changed its name to Predictive Oncology Inc. in June 2019. Predictive Oncology Inc. was incorporated in 2002 and is based in Eagan, Minnesota.
What does Predictive Oncology's logo look like?
Complete history of Daniel Handley stock trades at Predictive Oncology
Predictive Oncology executives and stock owners
Predictive Oncology executives and other stock owners filed with the SEC include:
-
Dr. Carl I. Schwartz,
CEO & Director -
Robert L. Myers,
CFO & Sec. -
David Johnson,
Senior Vice President - Operations -
Robert Myers,
Chief Financial Officer -
J. Melville Engle,
Chairman & CEO -
Richard L. Gabriel B.Sc, MBA,
Sr. VP of R&D -
Gregory St.Clair,
Independent Director -
Chuck Nuzum,
Independent Director -
Nancy Chung-Welch,
Independent Director -
Frank Mancuso,
Director -
Timothy Krochuk,
Director -
Ricardo Koenigsberger,
Director -
Daniel Handley,
Director -
H. Gabriel,
Director -
J. Engle,
Director -
Carl Schwartz,
President, Chief Executive Officer, Director -
Dr. Arlette H. Uihlein FCAP, M.D.,
Sr. VP of Regulatory Affairs & Quality -
Theresa Ferguson,
Sr. Director of Marketing -
Dr. Julia Kirshner Ph.D.,
Chief Scientific Officer -
Dr. Lawrence J. DeLucas D.Sc, O.D, Ph.D.,
Sr. VP of Operations -
Pamela Bush M.B.A., Ph.D.,
Sr. VP of Strategic Sales & Bus. Devel. -
Kevin Hungerford,
VP of Sales & Marketing -
David Stewart Smith,
-
Thomas J. Mc Goldrick,
Director -
Gerald J Jr Vardzel,
Director -
Veena Rao,
Director -
Pamela S Prior,
Director -
Charles Lee Sr Nuzum,
Director -
Matthew Hawryluk,
Director -
Christina Lee Md Jenkins,
-
Raymond F Vennare,
CHIEF EXECUTIVE OFFICER